An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, 12-month open label extension study, following Phase 1 Study
MON-2021-001, with a single dose of monepantel (MPL) once daily (QD) for the treatment of
individuals with MND.
Phase:
Phase 1
Details
Lead Sponsor:
PharmAust Ltd
Collaborators:
Calvary Health Care Bethlehem Macquarie University, Australia